COPENHAGEN, Oct 9 (Reuters) – Lung cancer patients on
Roche’s immune system-boosting drug Tecentriq lived on
average 4.2 months longer than those taking chemotherapy in a
pivotal study, pressuring…
The post Roche lung cancer drug success adds to pressure on Bristol appeared first on NASDAQ.